Piperacillin‐induced immune hemolysis: new cases and a concise review of the literature

Mayer, Beate; Yürek, Salih; Salama, Abdulgabar

doi:10.1111/j.1537-2995.2009.02544.x

Cited by 37 publications

(29 citation statements)

References 16 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far, piperacillin-induced immune haemolytic anaemia (PIHA) has been described as an acute and severe haemolytic anaemia resulting into life-threatening events 7. Interestingly, the majority of the patients reported with PIHA in previous studies suffered from CF 7 9…”

Section: Introductionmentioning

confidence: 99%

Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis

Meinus¹,

Schwarz

Mayer

et al. 2016

BMJ Case Reports

Self Cite

View full text Add to dashboard Cite

Piperacillin-tazobactam is an antipseudomonal antibiotic frequently used in patients with cystic fibrosis (CF) to treat pulmonary exacerbations. Drug-induced immune haemolytic anaemia is a rare complication during treatment with piperacillin. So far, piperacillin-induced immune haemolytic anaemia (PIHA) is regarded as an acute and severe haemolytic anaemia resulting into life-threatening events. Here we report on a patient with mild PIHA, which did not result in any clinical symptoms or necessity for treatment. To the best of our knowledge, this is the first case report of PIHA without an acute severe haemolytic anaemia. Further research is needed to clarify if this case is a solitary clinical manifestation of PIHA or if mild clinical courses of PIHA might be under-reported. Cases of PIHA have been largely reported in patients with CF. This unequal distribution maybe due to the frequent administration of piperacillin for pulmonary exacerbation in patients with CF or due to CF-related cofactors of yet unknown aetiology.

show abstract

Section: Introductionmentioning

confidence: 99%

Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis

Meinus¹,

Schwarz

Mayer

et al. 2016

BMJ Case Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…Six of the 12 positive tests were from patients with CF between the ages of 15 and 37 years. A recent report from the Institute for Transfusion Medicine in Berlin, Germany reported that 8 patients with piperacillin-induced DIIHA, 5 of whom had CF [11]. The Blood Center of Wisconsin, Inc., reported 5 cases of piperacillin antibodies over a 20 year period (the underlying diagnosis was not reported) [12].…”

Section: Frequency Of Adverse Reactionsmentioning

confidence: 96%

Antibiotic hypersensitivity in CF: Drug-induced life-threatening hemolytic anemia in a pediatric patient

Chavez

Mian²,

Scurlock³

et al. 2010

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Adverse reactions to antibiotics in patients with cystic fibrosis (CF) are a growing concern. We report the case of a pediatric patient with CF with multiple comorbidities and a history of drug reactions, who developed life-threatening piperacillin-induced immune hemolytic anemia. We review drug-induced hemolytic anemia (DIIHA) in particular, and antibiotic hypersensitivity in CF in general, including the frequency, pathogenesis, and risk factors. Finally, we discuss the treatment options and propose an algorithm for the management of drug-induced hypersensitivity reactions in patients with CF.

show abstract

“…En pratique, seules quelques classes médicamenteuses doivent être retenues : céphalosporines de 38 génération, pénicillines et anti-inflammatoires non stéroïdiens (AINS) [27,28]. L'hémolyse apparaît en moyenne après 6 jours de traitement lors d'une première administration et peut survenir à tout moment lors d'une réintroduction.…”

Section: Médicamenteuses Et/ou Immuno-allergiquesunclassified

Anémie hémolytique chez l’adulte : principales causes et démarche diagnostique

et al. 2011

View full text Add to dashboard Cite

Piperacillin‐induced immune hemolysis: new cases and a concise review of the literature

Abstract: To date approximately 26 patients with PIHA have been described and at least eight of these patients had cystic fibrosis. It is unclear whether patients with cystic fibrosis might be susceptible in developing PIHA.

Cited by 37 publications

References 16 publications

Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis

Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis

Antibiotic hypersensitivity in CF: Drug-induced life-threatening hemolytic anemia in a pediatric patient

Anémie hémolytique chez l’adulte : principales causes et démarche diagnostique

Contact Info

Product

Resources

About